AU - Moradimoghadam, F. AU - Khosravi Khorashad, A. AU - Mokhtarifar, A. TI - Comparison between quadruple therapy and triple therapy for eradication of Helicobacter Pylori in patients with chronic dyspepsia PT - JOURNAL ARTICLE TA - QHMS JN - QHMS VO - 14 VI - 4 IP - 4 4099 - http://imtj.gmu.ac.ir/article-1-474-en.html 4100 - http://imtj.gmu.ac.ir/article-1-474-en.pdf SO - QHMS 4 AB  - Background and Aim: Helicobacter pylori treatment is advised in all cases of chronic dyspepsia recently but despite several new drugs, treatment failure is probable yet and the choice method to eradicate Hpylori is contraversial. Materials and Methods: We studied all patients with chronic dyspepsia who referred to endoscopic ward of Imam Reza hospital. After demonstration of Helicobacter pylori infection by rapid urea’s test (RUT), these cases were divided into two groups randomly. The first group was treated by Metronidazole, Amoxicillin and Omeprazole and the second group was treated by previous drugs plus Bismuth Substrate for 2 weeks. Then drug side effects were asked during the first and second week and Helicobacter pylori eradication was evaluated by UBT (Urea Breath test) six weeks after the treatment. Results: Among 56 cases in this study 39.3% were male and 60.7% were female and 41-50 years cases were more frequent. 27 cases (48.2%) were treated by triple therapy and 29 patients (51.8%) were treated by quadruple therapy. Most common symptoms during the first week were abdominal pain and flatulence but during the second week the common side effect was flatulence. Although, treatment side effects were rare in the second week and only 25% of patients had significant symptom. Finally the total treatment success rate was 49% and Helicobacter pylori was eradicated according to UBT in 50% by triple therapy and 48% by quadruple therapy. The difference between two methods was not significant, although treatment success ratio was higher in young people. Conclusion: Triple therapy (Omeprazole, Amoxicillin and Metronidazole) is an effective regimen for the first line therapy in eradication of Helicobacter pylori especially in young people. CP - IRAN IN - Mashhad Medical University, Mashhad, Iran. LG - eng PB - QHMS PG - 13 PT - Original YR - 2009